Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (9599)	4/12/1999 10:52:00 AM
From: Arthur Radley	Read Replies (1) \| Respond to of 17367

" During the quarter, Genentech announced that based on positive Phase III results the company is starting the preparation of a regulatory filing seeking approval to market in the United States a thrombolytic therapy with improved product attributes, called TNK-t-PA (tenecteplase), for the treatment of heart attacks. Meanwhile, partner Boehringer Ingelheim is preparing regulatory filings for TNK-t-PA in Europe. Genentech decided to continue development of the anti-CD11a (hu1124) monoclonal antibody product for psoriasis in collaboration with Xoma Ltd., through Phase III clinical trials. " As you reported, we are in with some "good" company and this news is better than a "sharp stick in the eye".

To: aknahow who wrote (9599)	4/12/1999 11:35:00 AM
From: Bluegreen	Read Replies (3) \| Respond to of 17367

George, once again you let us down on the reporting.<g> PLEASE READ BELOW>>>>>>>>Including the events mentioned above, Genentech recently announced the following: -- Decided to continue development of the anti-CD11a (hu1124) monoclonal antibody product for psoriasis in collaboration with Xoma, Ltd., through Phase III clinical trials. Also, agreed with XOMA Ltd. to license its technology for pharmaceutical antibody production designed to reduce production costs and increase yields.<<<<<<<<<<<<<